Sanofi To Cut Price Of Insulin By 78%

Sanofi SA said it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co., Patrick Wingrove reported for Reuters.

Photo Insert: The French drugmaker will also extend its $35 out-of-pocket pricing program to all patients with commercial insurance using Lantus.

The French drugmaker will also extend its $35 out-of-pocket pricing program to all patients with commercial insurance using Lantus.

The move comes as US President Joe Biden pushed to extend to most Americans the $35 cap on out-of-pocket insulin costs made available to Medicare recipients by the Inflation Reduction Act.

In addition to Lantus, Sanofi said it will cut by 70% the list price for its fast-acting insulin, Apidra. Sanofi said it already offered a lower-priced version of Lantus but that it had not been taken up widely by insurance programs.

The branded list price of Lantus is $438.07 for the pre-filled pens and $292.07 for a 10 ml vial. Those would come down to $96 and $64, respectively.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic